Extended Data Fig. 6. REGN5381 reduces systolic blood pressure similar to SOC, with additive effects observed upon combination with some but not all SOC therapies.
The reduction in systolic blood pressure was assessed in telemetered normotensive NPR1hu/hu mice administered a single subcutaneous dose of REGN5381 either alone or in combination with SOC agents for the treatment of HF and hypertension at therapeutically relevant doses (n = 5–7 per treatment group; pooled placebo n = 36). ARNi, angiotensin receptor/neprilysin inhibitor; HF, heart failure; NPR1, natriuretic peptide receptor; NPR1hu/hu, NPR1 humanized; PDE, phosphodiesterase; RAAS, renin-angiotensin-aldosterone system; SGLT2, sodium-glucose cotransporter-2; SOC, standard-of-care.